Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

5.6%

5 terminated out of 90 trials

Success Rate

87.8%

+1.3% vs benchmark

Late-Stage Pipeline

8%

7 trials in Phase 3/4

Results Transparency

22%

8 of 36 completed with results

Key Signals

8 with results88% success

Data Visualizations

Phase Distribution

61Total
Not Applicable (22)
Early P 1 (3)
P 1 (17)
P 2 (12)
P 3 (3)
P 4 (4)

Trial Status

Completed36
Unknown23
Recruiting17
Terminated5
Withdrawn4
Active Not Recruiting3

Trial Success Rate

87.8%

Benchmark: 86.5%

Based on 36 completed trials

Clinical Trials (90)

Showing 20 of 20 trials
NCT00092222Phase 2Active Not Recruiting

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

NCT05886764Not ApplicableRecruiting

Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials

NCT04242095RecruitingPrimary

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

NCT07429123Completed

Using an Artificial Intelligence Medical Device to Help Primary Care Practitioners Identify and Manage Skin Conditions (Tumor, Inflammatory, and Infectious Diseases) in Adult Patients at Pozuelo and Majadahonda Health Centers

NCT03229837Completed

Validation Study of Pediatric Patient-Reported Outcomes

NCT06922825Early Phase 1Withdrawn

Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients

NCT07338006Not ApplicableRecruiting

Chest Wall Reconstruction Cohort

NCT07071909Phase 1WithdrawnPrimary

Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells

NCT06715839Not ApplicableRecruitingPrimary

Target-specific immunoPET Imaging of Digestive System Carcinoma

NCT01743131Phase 2Completed

Abatacept as GVHD Prophylaxis Phase 2

NCT05407844Not ApplicableEnrolling By Invitation

Community Health Worker Based Intervention to Improve Palliative Care

NCT05770544Phase 2Recruiting

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

NCT05770102Phase 2RecruitingPrimary

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

NCT06988475Phase 2Recruiting

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

NCT04656873Active Not RecruitingPrimary

Immuno-Oncology Database and Bioregistry

NCT06484231CompletedPrimary

Evaluation of the Effectiveness of Prophylactic LMWH by Thromboelastography

NCT05992363Not ApplicableRecruiting

Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction

NCT06789601Phase 1RecruitingPrimary

Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository

NCT06999785Not ApplicableNot Yet Recruiting

Assessment of the Impact of Increased Production of Reactive Oxygen Species Produced During Repeated Sessions of Hyperbaric Oxygen Therapy in Patients Undergoing Radiotherapy for Neoplasia, on the Occurrence of DNA Damage

NCT04122469Not ApplicableRecruitingPrimary

The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease

Scroll to load more

Research Network

Activity Timeline